MedTrace Logo

Postoperative Adjuvant Therapy of HCC Based on PD-1

NCT05307926 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 573

Last updated 2022-09-07

No results posted yet for this study

Summary

For the treatment of hepatocellular carcinoma, liver resection is still one of the optimal options, but the recurrence rate is as high as 70% five years after the operation, and the prognosis of patients with high-risk recurrence factors such as portal vein tumor thrombus and microvascular invasion is even worse, so it is particularly urgent to find effective postoperative adjuvant treatment. The role of PD-1 inhibitors in preventing the postoperative recurrence of HCC requires further study.

Conditions

Interventions

DRUG

PD-1 inhibitors

For patients with PVTT, they received adjuvant therapy of PD1 (200mg intravenously every 3 weeks for a total of 18cycles) plus Lenvatinib (8mg orally once a day for 1 year) 2-4 weeks after surgery; for patients with other high-risk factors for recurrence, they PD-1(200mg intravenously every 3 weeks for a total of 9cycles) monotherapy 2-4 weeks after surgery.

PROCEDURE

TACE

Patients with high-risk factors for recurrence received 1 TACE about a month after surgery.

Sponsors & Collaborators

  • Chen Xiaoping

    lead OTHER

Principal Investigators

  • xiaoping Dr Chen · Tongji Hospital

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-01
Primary Completion
2022-07-30
Completion
2022-08-20

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05307926 on ClinicalTrials.gov